Streetbeat News

RHHBY

Roche Holding AG

CEO

Severin Schwan

Industry

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

Open

35.88

Mkt cap

236B

Volume

211K

High

36.01

P/E Ratio

19.05

52-wk high

42.43

Low

35.76

Div yield

0.04

52-wk low

29.20

Gilead Sciences (GILD) faces speculation about entering the obesity drug market, but remains focused on liver treatments, particularly NASH. Despite a brief stock surge, analysts doubt Gilead's competitiveness in obesity drugs. Companies like Eli Lilly (LLY) and Novo Nordisk (NVO) lead the obesity drug market, while others like Pfizer (PFE) and Merck (MRK) explore opportunities.

Portfolio Pulse from Vandana Singh

June 21, 2024 | 3:42 pm

The FDA has approved the expanded use of Sarepta Therapeutics' (NASDAQ:SRPT) gene therapy Elevidys for Duchenne muscular dystrophy (DMD) to include both ambulatory and non-ambulatory patients aged 4 and above. Sarepta will conduct a confirmatory trial for non-ambulatory patients. The news follows disappointing results from Pfizer's (NYSE:PFE) Phase 3 study for a similar treatment.

Portfolio Pulse from Vandana Singh

June 21, 2024 | 11:39 am

Roche's VENTANA DP 200 Digital System has received FDA approval for diagnostic use, enabling pathologists to diagnose patients using digital images. This approval is a significant step in Roche's commitment to digital pathology solutions.

Portfolio Pulse from Benzinga Newsdesk

June 18, 2024 | 6:03 am

Genentech's Phase III STARGLO study shows that Columvi, in combination with chemotherapy, significantly increases survival rates for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The study met its primary endpoint with a 41% reduction in the risk of death. This treatment could offer a new option for patients ineligible for transplants.

Portfolio Pulse from Benzinga Newsdesk

June 17, 2024 | 7:47 am

Goldman Sachs has initiated coverage on Regenxbio Inc (NASDAQ:RGNX) with a Buy rating and a price target of $38, citing the potential of its gene therapy pipeline. The company's pipeline includes treatments for ophthalmology, Duchenne muscular dystrophy, and Hunter syndrome. Goldman Sachs anticipates that upcoming data releases and filings will boost Regenxbio's share performance.

Portfolio Pulse from Vandana Singh

June 07, 2024 | 6:30 pm

Italy's antitrust regulator is investigating Novartis AG and Roche Holdings AG-controlled Genentech for allegedly restricting competition in the sale of an eye drug, Byooviz. The probe focuses on potential delays in the Italian market launch of Byooviz, a biosimilar of Lucentis, due to coordinated strategies by these companies. The investigation could impact drug availability and prices for patients.

Portfolio Pulse from Vandana Singh

June 06, 2024 | 5:19 pm

Roche's Genentech has been granted Priority Review by the FDA for Inavolisib, an investigational oral therapy, in combination with Palbociclib (Ibrance) and Fulvestrant. The FDA decision is expected by November 27, 2024. This regimen targets PIK3CA-mutated, HR-positive, HER2-negative, locally advanced or metastatic breast cancer.

Portfolio Pulse from Benzinga Newsdesk

May 29, 2024 | 5:08 am

Roche and Hitachi High-Tech have extended their 46-year partnership to advance diagnostic testing. The renewed 10-year contract aims to accelerate the availability of new solutions, including the upcoming launches of cobas® c703 & ISE neo units and cobas® Mass Spec solution.

Portfolio Pulse from Benzinga Newsdesk

May 28, 2024 | 7:27 am

The Biden administration has urged the U.S. Supreme Court to reconsider a ruling involving 21 pharmaceutical and medical equipment companies accused of funding terrorism in Iraq, resulting in the deaths and injuries of American service members. The companies, including AstraZeneca, Pfizer, GE Healthcare, Johnson & Johnson, and F. Hoffmann-La Roche, allegedly engaged in corrupt practices to secure medical-supply contracts with a militia group. The Justice Department's request follows a precedent set in a previous case involving Twitter.

Portfolio Pulse from Vandana Singh

May 23, 2024 | 6:00 pm

JPMorgan has initiated coverage of Structure Therapeutics (NASDAQ:GPCR) with an 'Overweight' rating and a price target of $65, indicating an 80% potential upside. The company is developing an oral GLP-1 weight loss drug, '1290,' which could hit the market ahead of competitors. The obesity drug market is seeing significant developments, with Roche, Eli Lilly, Novo Nordisk, and Biohaven also making strides.

Portfolio Pulse from Benzinga Neuro

May 22, 2024 | 2:41 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.